Replies to post #45783 on Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

ADRO got the bad news ADXS is down and ADRO is up.

ADRO's news tells two things:
i) ADRO will not be wasting money on their Listeria-based trials as the Street likely thinks they'd rather focus on programs that may yield better outcomes. Their pancreatic trials failed a year (?) ago, thus the likelihood of these trials failing was somewhat baked in. News out, the numbers re-run and the stock is up.
ii) It reduces a probability of ADXS LM-based trials to be a success, at least what WS thinks.
That's my take.
PS. ADRO is now almost Listeria-free, and we should be technically decoupled from them.